1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Johmura, Y., et al., Necessary and sufficient role for a mitosis skip in senescence
induction. Mol Cell, 2014. 55(1): p. 73-84.
Alvarado-Ortiz, E., et al., Mutant p53 Gain-of-Function: Role in Cancer Development,
Progression, and Therapeutic Approaches. Front Cell Dev Biol, 2020. 8: p. 607670.
Kitao, H., et al., DNA replication stress and cancer chemotherapy. Cancer Sci, 2018.
109(2): p. 264-271.
Huang, P., et al., Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res,
1991. 51(22): p. 6110-7.
Kukhanova, M., et al., L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate
analogs as substrates for human DNA polymerases. Implications for the mechanism of
toxicity. J Biol Chem, 1995. 270(39): p. 23055-9.
Chen, Y.W., et al., A novel role of DNA polymerase eta in modulating cellular sensitivity
to chemotherapeutic agents. Mol Cancer Res, 2006. 4(4): p. 257-65.
Mayer, R.J., et al., Randomized trial of TAS-102 for refractory metastatic colorectal
cancer. N Engl J Med, 2015. 372(20): p. 1909-19.
Shitara, K., et al., Trifluridine/tipiracil versus placebo in patients with heavily pretreated
metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet Oncol, 2018. 19(11): p. 1437-1448.
Emura, T., et al., An optimal dosing schedule for a novel combination antimetabolite,
TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol
Med, 2004. 13(2): p. 249-55.
Tanaka, N., et al., Repeated oral dosing of TAS-102 confers high trifluridine
incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep,
2014. 32(6): p. 2319-26.
Sakamoto, K., et al., Crucial roles of thymidine kinase 1 and deoxyUTPase in
incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine
into DNA. Int J Oncol, 2015. 46(6): p. 2327-34.
Matsuoka, K., et al., Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with
Its Massive Misincorporation into DNA and Few DNA Strand Breaks. Mol Cancer Ther,
2015. 14(4): p. 1004-13.
Lin, P.F., S.Y. Zhao, and F.H. Ruddle, Genomic cloning and preliminary
characterization of the human thymidine kinase gene. Proc Natl Acad Sci U S A, 1983.
80(21): p. 6528-32.
Eriksson, S., et al., Comparison of the substrate specificities of human thymidine kinase 1
and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs.
Biochem Biophys Res Commun, 1991. 176(2): p. 586-92.
Johansson, N.G. and S. Eriksson, Structure-activity relationships for phosphorylation of
nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim Pol, 1996.
43(1): p. 143-60.
Murakami, Y., et al., Different mechanisms of acquired resistance to fluorinated
pyrimidines in human colorectal cancer cells. Int J Oncol, 2000. 17(2): p. 277-83.
Temmink, O.H., et al., Intracellular thymidylate synthase inhibition by trifluorothymidine
in FM3A cells. Nucleosides Nucleotides Nucleic Acids, 2004. 23(8-9): p. 1491-4.
65
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Naito, Y., et al., CRISPRdirect: software for designing CRISPR/Cas guide RNA with
reduced off-target sites. Bioinformatics, 2015. 31(7): p. 1120-3.
Cong, L., et al., Multiplex genome engineering using CRISPR/Cas systems. Science, 2013.
339(6121): p. 819-23.
Edahiro, K., et al., Thymidine Kinase 1 Loss Confers Trifluridine Resistance without
Affecting 5-Fluorouracil Metabolism and Cytotoxicity. Mol Cancer Res, 2018. 16(10): p.
1483-1490.
Dobrovolsky, V.N., et al., Mice deficient for cytosolic thymidine kinase gene develop
fatal kidney disease. Mol Genet Metab, 2003. 78(1): p. 1-10.
Dobrovolsky, V.N., et al., Effect of arylformamidase (kynurenine formamidase) gene
inactivation in mice on enzymatic activity, kynurenine pathway metabolites and
phenotype. Biochim Biophys Acta, 2005. 1724(1-2): p. 163-72.
Kitao, H., et al., The antibodies against 5-bromo-2'-deoxyuridine specifically recognize
trifluridine incorporated into DNA. Sci Rep, 2016. 6: p. 25286.
Takahashi, K., et al., Contribution of equilibrative nucleoside transporter(s) to intestinal
basolateral and apical transports of anticancer trifluridine. Biopharm Drug Dispos, 2018.
39(1): p. 38-46.
Takahashi, K., et al., Involvement of Concentrative Nucleoside Transporter 1 in Intestinal
Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells. J Pharm Sci,
2015. 104(9): p. 3146-53.
Gordon, H.L., et al., Comparative study of the thymidine kinase and thymidylate kinase
activities and of the feedbach inhibition of thymidine kinase in normal and neoplastic
human tissue. Cancer Res, 1968. 28(10): p. 2068-77.
He, Q., et al., Thymidine kinase 1 in serum predicts increased risk of distant or
loco-regional recurrence following surgery in patients with early breast cancer.
Anticancer Res, 2006. 26(6C): p. 4753-9.
Kolberg, M., et al., Protein expression of BIRC5, TK1, and TOP2A in malignant
peripheral nerve sheath tumours--A prognostic test after surgical resection. Mol Oncol,
2015. 9(6): p. 1129-39.
Wang, J., et al., Thymidine kinase 1 expression in ovarian serous adenocarcinoma is
superior to Ki-67: A new prognostic biomarker. Tumour Biol, 2017. 39(6): p.
1010428317706479.
Xu, Y., et al., Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1
adenocarcinoma of the lung. Int J Clin Exp Med, 2014. 7(8): p. 2120-8.
Xu, Y., et al., High thymidine kinase 1 (TK1) expression is a predictor of poor survival in
patients with pT1 of lung adenocarcinoma. Tumour Biol, 2012. 33(2): p. 475-83.
Yoshino, T., et al., Effect of thymidine kinase 1 expression on prognosis and treatment
outcomes in refractory metastatic colorectal cancer: Results from two randomized
studies of TAS-102 versus a placebo. Journal of Clinical Oncology, 2017. 35: p. 1.
Yoshino, T., et al., Relationship Between Thymidine Kinase 1 Expression and
Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled
Analysis of 2 Randomized Clinical Trials. Clin Colorectal Cancer, 2018. 17(4): p.
e719-e732.
Techer, H., et al., The impact of replication stress on replication dynamics and DNA
damage in vertebrate cells. Nat Rev Genet, 2017. 18(9): p. 535-550.
66
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
Halazonetis, T.D., V.G. Gorgoulis, and J. Bartek, An oncogene-induced DNA damage
model for cancer development. Science, 2008. 319(5868): p. 1352-5.
Dobbelstein, M. and C.S. Sorensen, Exploiting replicative stress to treat cancer. Nat Rev
Drug Discov, 2015. 14(6): p. 405-23.
Cimprich, K.A. and D. Cortez, ATR: an essential regulator of genome integrity. Nat Rev
Mol Cell Biol, 2008. 9(8): p. 616-27.
Ceccaldi, R., P. Sarangi, and A.D. D'Andrea, The Fanconi anaemia pathway: new
players and new functions. Nat Rev Mol Cell Biol, 2016. 17(6): p. 337-49.
Ishiai, M., et al., FANCI phosphorylation functions as a molecular switch to turn on the
Fanconi anemia pathway. Nat Struct Mol Biol, 2008. 15(11): p. 1138-46.
Andreassen, P.R., A.D. D'Andrea, and T. Taniguchi, ATR couples FANCD2
monoubiquitination to the DNA-damage response. Genes Dev, 2004. 18(16): p. 1958-63.
Durkin, S.G. and T.W. Glover, Chromosome fragile sites. Annu Rev Genet, 2007. 41: p.
169-92.
Chan, K.L., et al., Replication stress induces sister-chromatid bridging at fragile site loci
in mitosis. Nat Cell Biol, 2009. 11(6): p. 753-60.
Marusyk, A., et al., p53 mediates senescence-like arrest induced by chronic replicational
stress. Mol Cell Biol, 2007. 27(15): p. 5336-51.
Ewald, J.A., et al., Therapy-induced senescence in cancer. J Natl Cancer Inst, 2010.
102(20): p. 1536-46.
Ewald, B., D. Sampath, and W. Plunkett, Nucleoside analogs: molecular mechanisms
signaling cell death. Oncogene, 2008. 27(50): p. 6522-37.
Bijnsdorp, I.V., et al., Trifluorothymidine induces cell death independently of p53.
Nucleosides Nucleotides Nucleic Acids, 2008. 27(6): p. 699-703.
Nieminuszczy, J., R.A. Schwab, and W. Niedzwiedz, The DNA fibre technique - tracking
helicases at work. Methods, 2016. 108: p. 92-8.
Murakami, T., et al., Stable interaction between the human proliferating cell nuclear
antigen loader complex Ctf18-replication factor C (RFC) and DNA polymerase {epsilon}
is mediated by the cohesion-specific subunits, Ctf18, Dcc1, and Ctf8. J Biol Chem, 2010.
285(45): p. 34608-15.
Narita, T., et al., Human replicative DNA polymerase delta can bypass T-T (6-4)
ultraviolet photoproducts on template strands. Genes Cells, 2010. 15(12): p. 1228-39.
Shiomi, Y., et al., A second proliferating cell nuclear antigen loader complex,
Ctf18-replication factor C, stimulates DNA polymerase eta activity. J Biol Chem, 2007.
282(29): p. 20906-14.
Kiyonari, S., et al., The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces
p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate
Biosynthesis. Mol Cancer Ther, 2015. 14(10): p. 2332-42.
Arakawa, H., D. Lodygin, and J.M. Buerstedde, Mutant loxP vectors for selectable
marker recycle and conditional knock-outs. BMC Biotechnol, 2001. 1: p. 7.
Iimori, M., et al., Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic
progression and genome stability. Nat Commun, 2016. 7: p. 11117.
Okamoto, Y., et al., Replication stress induces accumulation of FANCD2 at central
region of large fragile genes. Nucleic Acids Res, 2018. 46(6): p. 2932-2944.
Krenning, L., et al., Transient activation of p53 in G2 phase is sufficient to induce
senescence. Mol Cell, 2014. 55(1): p. 59-72.
67
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
Ercilla, A., et al., Physiological Tolerance to ssDNA Enables Strand Uncoupling during
DNA Replication. Cell Rep, 2020. 30(7): p. 2416-2429 e7.
Lossaint, G., et al., FANCD2 binds MCM proteins and controls replisome function upon
activation of s phase checkpoint signaling. Mol Cell, 2013. 51(5): p. 678-90.
Sakaue-Sawano, A., et al., Visualizing spatiotemporal dynamics of multicellular
cell-cycle progression. Cell, 2008. 132(3): p. 487-98.
Vassilev, L.T., et al., Selective small-molecule inhibitor reveals critical mitotic functions
of human CDK1. Proc Natl Acad Sci U S A, 2006. 103(28): p. 10660-5.
Temmink, O.H., et al., Therapeutic potential of the dual-targeted TAS-102 formulation in
the treatment of gastrointestinal malignancies. Cancer Sci, 2007. 98(6): p. 779-89.
Kroep, J.R., et al., Sequence dependent effect of paclitaxel on gemcitabine metabolism in
relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer,
2000. 83(8): p. 1069-76.
Debatisse, M., et al., Common fragile sites: mechanisms of instability revisited. Trends
Genet, 2012. 28(1): p. 22-32.
Tubbs, A., et al., Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork
Collapse. Cell, 2018. 174(5): p. 1127-1142 e19.
Toledo, L.I., et al., ATR prohibits replication catastrophe by preventing global
exhaustion of RPA. Cell, 2013. 155(5): p. 1088-103.
Tsuda, M., et al., The dominant role of proofreading exonuclease activity of replicative
polymerase epsilon in cellular tolerance to cytarabine (Ara-C). Oncotarget, 2017. 8(20):
p. 33457-33474.
Feng, L., et al., Role of p53 in cellular response to anticancer nucleoside analog-induced
DNA damage. Int J Mol Med, 2000. 5(6): p. 597-604.
Jackson, J.G., et al., p53-mediated senescence impairs the apoptotic response to
chemotherapy and clinical outcome in breast cancer. Cancer Cell, 2012. 21(6): p.
793-806.
Milanovic, M., et al., Senescence-associated reprogramming promotes cancer stemness.
Nature, 2018. 553(7686): p. 96-100.
Matsuoka, K., et al., Trifluridine/tipiracil overcomes the resistance of human gastric
5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget,
2018. 9(17): p. 13438-13450.
Temmink, O.H., et al., Trifluorothymidine resistance is associated with decreased
thymidine kinase and equilibrative nucleoside transporter expression or increased
secretory phospholipase A2. Mol Cancer Ther, 2010. 9(4): p. 1047-57.
Sabapathy, K. and D.P. Lane, Therapeutic targeting of p53: all mutants are equal, but
some mutants are more equal than others. Nat Rev Clin Oncol, 2018. 15(1): p. 13-30.
Auer, H., et al., Characterisation of genotoxic properties of 2',2'-difluorodeoxycytidine.
Mutat Res, 1997. 393(1-2): p. 165-73.
Zhang, H. and C.H. Freudenreich, An AT-rich sequence in human common fragile site
FRA16D causes fork stalling and chromosome breakage in S. cerevisiae. Mol Cell, 2007.
27(3): p. 367-79.
Kaushal, S. and C.H. Freudenreich, The role of fork stalling and DNA structures in
causing chromosome fragility. Genes Chromosomes Cancer, 2019. 58(5): p. 270-283.
68
75.
76.
77.
78.
Kaushal, S., et al., Sequence and Nuclease Requirements for Breakage and Healing of a
Structure-Forming (AT)n Sequence within Fragile Site FRA16D. Cell Rep, 2019. 27(4): p.
1151-1164 e5.
Irony-Tur Sinai, M., et al., AT-dinucleotide rich sequences drive fragile site formation.
Nucleic Acids Res, 2019. 47(18): p. 9685-9695.
Walsh, E., et al., Mechanism of replicative DNA polymerase delta pausing and a
potential role for DNA polymerase kappa in common fragile site replication. J Mol Biol,
2013. 425(2): p. 232-43.
Li, S. and X. Wu, Common fragile sites: protection and repair. Cell Biosci, 2020. 10: p.
29.
69
...
論文の公開元へ
